Apellis’ Syfovre Sales Overshadowed By Safety Concerns

Apellis Pharmaceuticals, Inc. has been on a fast-growth trajectory driven by the launch of Syfovre (pegcetacoplan injection), the first drug approved by the US Food and Drug Administration for geographic atrophy, secondary to age-related macular degeneration (AMD). The early launch performance has been outpacing investor expectations, but the emergence of events of retinal vasculitis in the real-world setting threatens to curb near-term growth.

The company announced second quarter financial results on 31 July with Syfovre generating $67.3m, more than some analysts had previously anticipated the drug would generate in its first year. Nonetheless, the financial update was overshadowed by the safety update